Translator Disclaimer
1 March 2009 Fluorescent immunolabeling of cancer cells by quantum dots and antibody scFv fragment
Author Affiliations +
Abstract
Semiconductor quantum dots (QDs) coupled with cancer-specific targeting ligands are new promising agents for fluorescent visualization of cancer cells. Human epidermal growth factor receptor 2/neu (HER2/neu), overexpressed on the surface of many cancer cells, is an important target for cancer diagnostics. Antibody scFv fragments as a targeting agent for direct delivery of fluorophores offer significant advantages over full-size antibodies due to their small size, lower cross-reactivity, and immunogenicity. We have used quantum dots linked to anti-HER2/neu 4D5 scFv antibody to label HER2/neu-overexpressing live cells. Labeling of target cells was shown to have high brightness, photostability, and specificity. The results indicate that construction based on quantum dots and scFv antibody can be successfully used for cancer cell visualization.

1.

Introduction

The biological application of nanoparticles is a rapidly developing area of nanotechnology that raises new possibilities in the diagnostics and treatment of human cancers.1, 2

Semiconductor quantum dots (QDs) are tiny light-emitting particles on the nanometer scale and represent a new class of fluorescent labels for biology and medicine. Compared with conventional fluorophores (organic dyes and fluorescent proteins), quantum dots have unique optical properties, offering advantages for biomedical application. These are size-tunable symmetric narrow emission spectrum, broad absorption spectrum, and high resistance to photobleaching.3, 4 In cancer diagnostics, fluorescent nanoparticles such as QDs coupled with cancer-specific targeting carriers are highly promising agents for fluorescent labeling and determination of immune status of tumors, as well as for visualizing of peripheral metastases.5

The object of our study was human epidermal growth factor receptor 2/neu (HER2/neu) overexpressed cancer cells. HER2/neu overexpression correlates with poor prognosis for patient treatment and high chemotherapy resistance. Therefore, detection of HER2/neu-overexpressing cells is of great clinical importance.6, 7 Antibodies against cancer markers located on the surface of tumor cells (e.g., cell surface antigens or receptors overexpressed in cancer cells) are excellent targeting agents ensuring directed delivery of fluorescent nanoparticles to the tumor. A number of studies have demonstrated the feasibility of coupling QDs to a variety of antibodies for tumor targeting. QDs coupled with full-size monoclonal anti-HER2/neu antibodies have been successfully used for fluorescent detection of HER2/neu-overexpressing cancer cells.8, 9, 10, 11 The antibodies were bound to nanocrystals by cross-linking reagents or using a three-layer labeling strategy based on a biotin-streptavidin system (primary antibody followed by biotinylated secondary antibody, followed by streptavidin-QDs conjugate).

Recently, constructions based on antibody fragments are regarded to be promising as targeting agents for medicine. These small fragments of antibody, while retaining the same binding specificity, are more efficient at penetrating tumor masses because of their smaller size, do not interact with receptors of immune system cells and proteins of the complement system, and are more effectively cleared from the circulation. One of the variants of such constructions is single-chain Fv fragment (scFv)—recombinant polypeptide in which variable domains of heavy and light chains (VL and VH) are connected by a flexible linker.12 Such small-size (25to30kDa) antibody fragments show improved tumor penetration, more homogenous tissue distribution, and much more rapid blood clearance properties compared with intact antibody when used in vivo.12, 13, 14 These characteristics make them potentially more useful carriers of nanoparticles.

In this work, we describe a fluorescent complex for specific visualization of HER2/neu overexpressing cells using CdSeCdS core-shell QDs and anti-HER2/neu 4D5 scFv, which are characterized by serum stability and ability of highly effective coupling with its antigen-target—extracellular domain of HER2/neu.15 QDs were bound to 4D5 scFv by a previously described barnase-barstar system analogous to the streptavidin-biotidin system.16

2.

Materials and Methods

2.1.

Synthesis and Solubilization of Nanocrystals

CdSe QD cores caped with oleic acid were synthesized by a high-temperature method using high-boiling organic solvent starting from cadmium oleate and trioctylphosphine selenide, as we described earlier.17 Core sizes were obtained by luminescent spectroscopy using luminescence wavelength dependence on CdSe QD size.18

An analogous method with trioctylphosphine sulfide was used for CdS shell growth. CdSe QD cores ( 50mg in 1ml hexane) were added to cadmium oleate solution ( 0.5mmol in 5ml hexadecane pure, made as described for diphenylether), and the mixture was rapidly heated under argon atmosphere. When reaction mixture temperature was near 250°C , 0.5ml 1M trioctylphosphine sulfide [(C8H17)3PS] solution in trioctylphosphine was injected in the reaction mixture with vigorous stirring. The temperature was stabilized at 250°C for 15min for growth of CdS shell. Isolation and purification of the obtained CdSeCdS heterostructures were analogous for CdSe cores.

QDs were treated with mercaptoacetic acid (MAA, HSCH2COOH ), which allows transferring them into water solution. For ligand exchange, MAA was slowly added to hexane solution of CdSeCdS with vigorous stirring at room temperature. When QD coagulation was detected, MAA addition was finished, and the reaction mixture was stirred about 30min . Twofold MAA quantity was typically required to exchange oleate CCO groups on QDs surfaces. MAA-modified QDs were initially water insoluble, but low ammonia addition resulted in solubility of QDs in water.

The composition and optical properties of synthesized QDs were examined by UV-VIS absorbance, IR, and photoluminescence spectroscopy.

The optical absorption spectra were obtained with Perkin-Elmer Lambda-35 for UV-VIS and SpectrumOne for IR range spectrometers.

For IR measurement, the QDs were precipitated by ethyl ether and dried under vacuum. IR spectra were registered using a solid-state sampler for SpectrumOne with ZnSe/diamond optics.

The fluorescence spectra of water solutions of unconjugated QDs and barstar-QDs were obtained with Cary Eclipse (Varian) fluorescence spectrophotometer. QDs were excited at 350nm .

2.2.

Isolation and Purification of Proteins

Isolation and purification of barstar (monoalanine mutant C40A containing the cysteine residue at position 82 only) were performed by the method described in Ref. 19, with modifications. To produce barstar, E.coli HB101 was transformed with pMT641 plasmid.20 Transformed cells were grown in YTPS broth (1% yeastrel, 1% trypton, 0.5% NaCl, 80mM K2HPO4 , 20mM KH2PO4 , 2mM MgCl2 , 0.1gl ampicillin, pH 7.4) at 37°C until a stationary growth phase was attained, and then the cells were harvested by centrifugation at 7000g for 10min at 4C .

Further, the cells were resuspended in lysis buffer ( 20mM Tris, 10mM KH2PO4 , 10nM EDTA, 10mM 1,4-ditiothreitol, 100mM NaCl, pH 8.0) and sonicated on ice. The obtained lysate was clarified by centrifugation at 18,500g , nucleic acids were precipitated by 0.04% polyethyleneimine, and proteins were fractionated by step salting-out of ammonium sulphate. A 40 to 80% fraction was solved in 0.1M tris-HCl, 10mM EDTA, 10mM 1,4-ditiothreitol (pH 8.0) buffer and applied on a C16/100 column with 180ml superfine sephadex G-100 balanced by TSDT buffer ( 20mM Tris, 20mM NaCl, 2mM 1,4-ditiothreitol, 0.05% Tween-20, pH 8.5). 115to140ml eluate fraction was applied on a HiTrap with FastFlow Qsepharose 1ml (GE Healthcare), washed subsequently by TSDT and TDG buffer ( 20mM Tris, 4mM 1,4-ditiothreitol, 10% glycerin, pH 8.5) and eluted by NaCl concentration gradient from 0to1M in TDG buffer. Homogeneous barstar was eluated with 100mM NaCl.

4D5 scFv-dibarnase fusion protein was extracted using the procedure described in Ref. 16.

2.3.

Synthesis of QD-Barstar Conjugate

The resultant MAA-modified QDs were conjugated with barstar using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, Sigma) as a cross-linker. QDs in 20mM borate buffer pH 6.5 were first activated with EDC at room temperature for 15min . The mixture was then purified through Sephadex G-25 column eluted with 20mM borate buffer pH 7.4. Subsequently, barstar in the same buffer was added to the solution and reacted for 1h at room temperature. Unbound protein was separated by Sephadex G-25 column eluated with PBS buffer pH 7.4. QDs, barstar, and EDC were mixed in molar ratio of 1:20:20, respectively.

2.4.

Cell Cultures and Immunofluorescent Labeling

Human breast cancer SKBR-3 cells (HTB 30, ATCC) were seeded in 96-well plates (Corning, New York) containing RPMI-1640 medium (PanEco, Russia) with 10% fetal calf serum (HyClone, Belgium) and 2mM L-glutamine, at density up to 2×103 cell per well and cultured at 37°C with 5% CO2 overnight.

The ingredients used for incubation were dissolved in 100μl PBS (pH 7.4) with 1% fetal calf serum, 25mM 2-deoxyglucose, and 0.01% sodium azide.

Unfixed live cells were gently washed twice with PBS (pH 7.4). The cells were then incubated on ice sequentially with 10μgml 4D5 scFv-dibarnase that binds to the external domain of HER2/neu, and 80nM barstar-conjugated QDs for 40min each. Barstar-QD conjugates without antibody were incubated with the cells and served as a control.

Cells were imaged live using a Zeiss Axiovert 200 inverted epifluorescence microscope with a 40×lens and an AxioCam HRc CCD camera (Zeiss). Bright-field images were collected using phase contrast mode. QDs were excited at 332to382nm with a mercury lamp as a light source. QD fluorescent images were collected using a 575to640-nm emission filter.

3.

Results and Discussion

CdSeCdS core-shell, 3.5-nm -diam QDs, synthesized by high-temperature method, were soluble only in nonpolar solvents (hexane, chloroform). Presence of COO vibration bands in the absence of –COOH vibrational bands at IR spectrum (Fig. 1, dashed line) revealed that the as-synthetized QDs capped with oleate-ions, but not with the oleic acid itself.

Fig. 1

IR spectra of QDs capped with oleic acid (dashed line) and mercaptoacetic acid (solid line).

021004_1_071902jbo1.jpg

Biocompatible water-soluble QDs were obtained by modifying the surface with mercaptoacetic acid (MAA)—a bifunctional compound capable of replacing oleate-anions on the surface of nanocrystals and containing hydrophilic groups that provide water solubility. This method of nanocrystal solubilization is widely used21 and was chosen because of its convenience and simplicity.

IR spectroscopy (Fig. 1, solidline) revealed successful replacing of hydrophobic oleae-anions by mercaptoacetic residues: C-H vibrational band intensity at around 3000cm1 significantly decreased, COO groups remained, and the C-S vibrational band at around 500cm1 appeared. The simultaneous presence of C-S vibrational band and absence of S-H vibrational band (Fig. 1, solidline) reveal that MAA molecule binds to QD surface using mercapto-group, but not carboxyl group. The latter group remains free (in COO ion form) for conjugation to proteins.

Water-soluble nanocrystals retained their nonaggregate state and fluorescence ability. Figure 2 (solidline) presents the fluorescence spectrum of water-soluble QDs with emission centered at 605nm .

Fig. 2

Fluorescence spectra with absorption normalized at the excitation (λexc=350) of water-soluble MAA-coated quantum dots (solid line) and QD-barstar conjugates (dashed line).

021004_1_071902jbo2.jpg

Immunofluorescent labeling, cell imaging, and other biological applications required creating of target QD-antibody constructions. Couples of specific molecules that are not sticky themselves but can stick only to each other provide a good opportunity for QD-based construction design. In this work, the previously described barnase-barstar module16 was used for binding Qds to scFv antibody. Bacterial ribonuclease from Bacillus amyloliquefaciens barnase and barstar, its natural inhibitor, are small-size proteins (12 and 10kDa , respectively) that are highly affine to each other (Кd1014M) . Conjugation of one of these proteins to some antibody and the other to QDs provides a directed delivery of QDs to the target of interest. This construction can be used as molecular “LEGO bricks,”22 allowing us to obtain complex of once conjugated to barstar or barnase QDs and different antibody. In this context, the barnase-barstar module can be compared only to the biotin-streptavidin system but, in contrast to it, has some advantages.22

To perform subsequent studies, MAA-coated QDs were conjugated to the barstar protein, a component of the barnase-barstar module.

It was observed that MAA-modified QDs precipitated in 3to4days . Barstar-conjugated QDs remained dissolved for at least 2to2.5weeks in the same conditions. Figure 2 presents fluorescence spectra with absorption normalized at the excitation of water-soluble MAA-coated quantum dots and QD-barstar conjugates. The spectra at Fig. 2 indicate that quantum yield of fluorescence was enhanced about three times after QDs conjugation to barstar. A red shift of the fluorescence peak (608nm) , as compared with that of unconjugated QDs (605nm) was also observed.

So, barstar-QD conjugates (as well as water-soluble QDs) retain their nonaggregate state and ability to fluoresce. The conjugation allows not only QDs binding to fusions of different antibodies with barnase, but also, enhanced quantum yield and stability of MAA-coated QDs in water solutions.

A low fluorescence quantum yield as well as insufficient stability of QDs solubilized using MAA were noted earlier by other authors.23, 24, 25 This is presumably determined by the dynamical character of MAA molecules bound with nanocrystal surface (S–S and/or Cd–S bonds). Stabilization of nanocrystals and increased quantum yield of fluorescence after formation of conjugates with small proteins (such as barstar) may be explained by the change of polarity of quantum dots in the environment and by neutralization of surface charge, as was demonstrated by other authors.26 Another possible explanation in the case of cystein-containing barstar mutant used in our work is additional passivation due to protein SH-groups linking to the surface of a quantum dot.

The applicability of the barnase-barstar module for target delivery of QDs was examined by the example of HER2/neu-overexpressing cell imaging.

HER2/neu belong to the epidermal growth factor receptor (EGFR) family. Family members are found on the surface of eukaryote cells and generally play a role in the regulation of cellular growth and differentiation. Homodimerization and heterodimerization among family members promote signal transduction cascade and cellular proliferation.27

Modular targeting molecules with 4D5 scFv antibody fusion to two barnase molecules in series were used as a carrier for QD-barstar. We have shown earlier that such molecules very efficiently bind to the external domain of HER2/neu cancer marker.16, 28 The QD-barstar conjugates effectively stained HER2/neu on the surface of human breast cancer SKBR-3 cells after the cells were incubated with a 4D5 scFv-dibarnase. When the cells were incubated with QD-barstar alone, weak or no detectable signal was observed on the cell surface, indicating that the QD-barstar conjugates have very low nonspecific binding (Fig. 3 ).

Fig. 3

Detection of HER2/neu-overexpressing SKBR-3 cells with QDs and 4D5 scFv. Top row: Fluorescence channel. Bottom row: bright-field images. Left: Live breast cancer SKBR-3 cells were incubated with 4D5 scFv-dibarnase and QD-barstar conjugate. Right: Cells were incubated with QD-barstar conjugates only.

021004_1_071902jbo3.jpg

To conclude, we have demonstrated effective application of CdSeCdS semiconductor nanocrystals obtained in our research for visualization of HER2/neu-overexpressing cancer cells using 4D5 scFv antibodies and the barnase-barstar system. Such target fluorescent complexes may be useful tools for different applications in cellular biology, immunohistochemistry, and intravital cancer imaging.

Acknowledgments

This work was partially supported by the Russian Foundation for Basic Research (Projects Nos. 09-04-01201-a, 07-04-01586, 07-04-00584, 07-02-00649, and 08-02-01293), RAS Presidium Programs “Fundamental Sciences for Medicine” and “Molecular and Cell Biology,” and Federal Agency for Science and Innovation (Project N02.522.11.2002).

References

1. 

Jain K. K., “Applications of nanobiotechnology in clinical diagnostics,” Clin. Chem., 53 (11), 2002 –2009 (2007). https://doi.org/10.1373/clinchem.2007.090795 0009-9147 Google Scholar

2. 

Yezhelyev M. V., Gao X., Xing Y., Al-Hajj A., Nie S., O’Regan R. M., “Emerging use of nanoparticles in diagnosis and treatment of breast cancer,” Lancet Oncol., 7 (8), 657 –667 (2006). https://doi.org/10.1016/S1470-2045(06)70793-8 1470-2045 Google Scholar

3. 

Bruchez M., Moronne M., Gin P., Weiss S., Alivisatos A. P., “Semiconductor nanocrystals as fluorescent biological labels,” Science, 281 (5385), 2013 –2016 (1998). https://doi.org/10.1126/science.281.5385.2013 0036-8075 Google Scholar

4. 

Chan W. C. W., Nie S., “Quantum dot bioconjugates for ultrasensitive nonisotopic detection,” Science, 281 (5385), 2016 –2018 (1998). https://doi.org/10.1126/science.281.5385.2016 0036-8075 Google Scholar

5. 

Gao X., Cui Y., Levenson R. M., Chung L. W. K., Nie S., “In vivo cancer targeting and imaging with semiconductor quantum dots,” Nat. Biotechnol., 22 (8), 969 –976 (2004). https://doi.org/10.1038/nbt994 1087-0156 Google Scholar

6. 

Ross J. S., Fletcher J. A., “The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy,” Oncologist, 3 (4), 237 –252 (1998). 1083-7159 Google Scholar

7. 

Nunes R. A., Harris L. N., “The HER2 extracellular domain as a prognostic and predictive factor in breast cancer,” Clin. Breast Cancer, 3 (2), 125 –135 (2002). https://doi.org/10.3816/CBC.2002.n.017 Google Scholar

8. 

Wu X., Liu H., Liu J., Haley K. N., Treadway J., Larson J. P., Ge N., Peale F., Bruchez M. P., “Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots,” Nat. Biotechnol., 21 (1), 41 –46 (2003). https://doi.org/10.1038/nbt764 1087-0156 Google Scholar

9. 

Li-Shishido S., Watanabe T. M., Tada H., Higuchi H., Ohuchi N., “Reduction in nonfluorescence state of quantum dots on an immunofluorescence staining,” Biochem. Biophys. Res. Commun., 351 (1), 7 –13 (2006). https://doi.org/10.1016/j.bbrc.2006.09.159 0006-291X Google Scholar

10. 

Tada H., Higuchi H., Wanatabe T. M., Ohuchi N., “In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice,” Cancer Res., 67 (3), 1138 –1144 (2007). https://doi.org/10.1158/0008-5472.CAN-06-1185 0008-5472 Google Scholar

11. 

Takeda M., Tada H., Higuchi H., Kobayashi Y., Kobayashi M., Sakurai Y., Ishida T., Ohuchi N., “In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine,” Breast Cancer, 15 (2), 145 –152 (2008). https://doi.org/10.1007/s12282-008-0037-0 Google Scholar

12. 

Bird R. E., Hardman K. D., Jacobson J. W., Johnson S., Kaufman B. M., Lee S. M., Lee T., Pope S. H., Riordan G. S., Whitlow. M., “Single-chain antigen-binding proteins,” Science, 242 (4877), 423 –426 (1988). https://doi.org/10.1126/science.3140379 0036-8075 Google Scholar

13. 

Trail P. A., King H. D., Dubowchik G. M., “Monoclonal antibody drug immunoconjugates for targeted treatment of cancer,” Cancer Immunol. Immunother., 52 (5), 328 –337 (2003). 0340-7004 Google Scholar

14. 

Wu A. M., Senter P. D., “Arming antibody: prospects and challenges for immunoconjugates,” Nat. Biotechnol., 23 (9), 1137 –1146 (2005). https://doi.org/10.1038/nbt1141 1087-0156 Google Scholar

15. 

Willuda J., Honegger A., Waibel R., Schubiger P. A., Stahel R., Zangemeister-Wittke U., Plückthun A., “High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment,” Cancer Res., 59 (22), 5758 –5767 (1999). 0008-5472 Google Scholar

16. 

Deyev S. M., Waibel R., Lebedenko E. N., Schubiger A. P., Pluckthun A., “Design of multivalent complexes using the barnase-barstar module,” Nat. Biotechnol., 21 (12), 1486 –1492 (2003). https://doi.org/10.1038/nbt916 1087-0156 Google Scholar

17. 

Vasiliev R. B., Dorofeev S. G., Dirin D. N., Belov D. A., Kuznetsova T. A., “Synthesis and optical properties of PbSe and CdSe colloidal quantum dots capped with oleic acid,” Mendeleev Commun., 14 (4), 169 –171 (2004). https://doi.org/10.1070/MC2004v014n04ABEH001970 0959-9436 Google Scholar

18. 

Peng X., Wickham J., Alivisatos A. P., “Kinetics of II-VI and III-V colloidal semiconductor nanocrystal growth: ‘focusing’ of size distributions,” J. Am. Chem. Soc., 120 (21), 5343 –5344 (1998). https://doi.org/10.1021/ja9805425 0002-7863 Google Scholar

19. 

Protasevich I. I., Schulga A. A., Vasilieva L. I., Polyakov K. M., Lobachov V. M., Hartley R. W., Kirpichnikov M. P., Makarov A. A., “Key role of barstar Cys-40 residue in the mechanism of heat denaturation of bacterial ribonuclease complexes with barstar,” FEBS Lett., 445 (2–3), 384 –388 (1999). https://doi.org/10.1016/S0014-5793(99)00158-1 0014-5793 Google Scholar

20. 

Hartley R. W., “Barnase and barstar. Expression of its cloned inhibitor permits expression of a cloned ribonucleas,” J. Mol. Biol., 202 (4), 913 –915 (1988). https://doi.org/10.1016/0022-2836(88)90568-2 0022-2836 Google Scholar

21. 

Hoshino A., Fujioka K., Oku T., Suga M., Sasaki Y., Ohta T. S., Yasuhara M., Suzuki K., Yamamoto K., “Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification,” Nano Lett., 4 (11), 2163 –2169 (2004). https://doi.org/10.1021/nl048715d 1530-6984 Google Scholar

22. 

Deyev S. M., Lebedenko E. N., “Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design,” BioEssays, 30 (9), 904 –918 (2008). https://doi.org/10.1002/bies.20805 0265-9247 Google Scholar

23. 

Bullen C., Mulvaney P., “The effects of chemisorption on the luminescence of CdSe quantum dots,” Langmuir, 22 (7), 3007 –3013 (2006). https://doi.org/10.1021/la051898e 0743-7463 Google Scholar

24. 

Xue F. L., Chen J. Y., Guo J., Wang C. C., Yang W. L., Wang P. N., Lu D. R., “Enhancement of intracellular delivery of CdTe quantum dots (QDs) to living cells by Tat conjugation,” J. Fluoresc., 17 (2), 149 –154 (2007). https://doi.org/10.1007/s10895-006-0152-2 1053-0509 Google Scholar

25. 

Sukhanova A., Devy J., Venteo L., Kaplan H., Artemyev M., Oleinikov V., Klinov D., Pluot M., Cohen J. H., Nabiev I., “Biocompatible fluorescent nanocrystals for immunolabeling of membrane proteins and cells,” Anal. Biochem., 324 (1), 60 –67 (2004). https://doi.org/10.1016/j.ab.2003.09.031 0003-2697 Google Scholar

26. 

Mattoussi H., Mauro J. M., Goldman E. R., Anderson G. P., Sundar V. C., Mikulec F. V., Bawendi M. G., “Self-assembly of CdSe–ZnS quantum dot bioconjugates using an engineered recombinant protein,” J. Am. Chem. Soc., 122 (49), 12142 –12150 (2000). https://doi.org/10.1021/ja002535y 0002-7863 Google Scholar

27. 

Wieduwilt M. J., Moasser M. M., “The epidermal growth factor receptor family: biology driving targeted therapeutics,” Cell. Mol. Life Sci., 65 1566 –1584 (2008). https://doi.org/10.1007/s00018-008-7440-8 1420-682X Google Scholar

28. 

Lebedenko E. N., Balandin T. G., Edelweiss E. F., Georgiev O., Moiseeva E. S., Petrov R. V., Deyev S. M., “Visualization of cancer cells by means of the fluorescent EGFP-barnase protein,” Dokl. Biochem. Biophys., 414 120 –123 (2007). https://doi.org/10.1134/S1607672907030088 Google Scholar
© (2009) Society of Photo-Optical Instrumentation Engineers (SPIE)
Tatiana A. Zdobnova, S. G. Dorofeev, P. N. Tananaev, R. B. Vasiliev, T. G. Balandin, Eveline F. Edelweiss, O. A. Stremovskiy, Irina V. Balalaeva, Ilya V. Turchin, Elena N. Lebedenko, Vladimir P. Zlomanov, and Sergey M. Deyev "Fluorescent immunolabeling of cancer cells by quantum dots and antibody scFv fragment," Journal of Biomedical Optics 14(2), 021004 (1 March 2009). https://doi.org/10.1117/1.3122775
Published: 1 March 2009
JOURNAL ARTICLE
5 PAGES


SHARE
Advertisement
Advertisement
Back to Top